Octreotide Benefits: What Studies Report

Octreotide is a prescription medicine. It is a synthetic analogue of the hormone somatostatin and is supplied as a short-acting injection, a long-acting depot injection given by a health professional, and an oral delayed-release capsule approved for long-term maintenance in acromegaly. This page is for educational purposes only and is not medical advice; consult a licensed physician or other qualified prescriber about whether any medicine is appropriate in an individual situation.

In the pages that follow, the word "benefit" is used only in the sense of outcomes that researchers measured and reported in published trials and reviews, at the level of the approved label indications. Nothing here is a statement that a given result will occur for any particular person, and no dosing instructions are given.

Approved Label Indications, Stated Plainly

In the United States, octreotide acetate injection is approved for the reduction of growth hormone and IGF-1 levels in acromegaly, for the symptomatic control of severe diarrhoea and flushing episodes associated with metastatic carcinoid tumours, and for the control of profuse watery diarrhoea associated with vasoactive intestinal peptide secreting tumours. The long-acting depot formulation carries corresponding long-term indications for patients who have responded to and tolerated the short-acting form, and an oral delayed-release capsule is approved for long-term maintenance in acromegaly. Labelling wording and the exact scope of indications differ between regulatory agencies, and a prescribing clinician or pharmacist can confirm what applies locally.

Outcome Domains at a Glance

Acromegaly: Hormone Control Endpoints

Acromegaly is the indication most closely associated with octreotide in the clinical literature. A review of octreotide in acromegaly described the drug's mechanism through somatostatin receptor subtypes and treated biochemical control, meaning reduction of growth hormone and IGF-1 concentrations, as the principal efficacy endpoint across the clinical programme, while also discussing tolerability and the development of long-acting formulations (PMID 30754185). That review characterised responses as varying between patients rather than uniform, which is why prescribers monitor hormone levels over time rather than assuming a fixed result.

Tumour size change in growth hormone secreting pituitary adenomas is a secondary endpoint discussed in the same review of octreotide in acromegaly (PMID 30754185). Readers looking for head-to-head comparisons between octreotide and other medical therapies for acromegaly will find that such comparisons are not covered by the papers cited on this page.

Carcinoid Syndrome and VIPoma Symptoms

Symptomatic control of diarrhoea and flushing in metastatic carcinoid tumours, and of watery diarrhoea in VIP-secreting tumours, sits within the approved labelling described above. The citation set used for this page does not include a dedicated randomised trial of symptom scores in carcinoid syndrome or VIPoma, so no numerical claim about flushing frequency or stool frequency is made here. A review of somatostatin analogues in gastroenteropancreatic neuroendocrine tumours discussed this class in the broader management of functioning tumours alongside its antiproliferative effects (PMID 20572298). Where a reader is looking for symptom-control numbers, the honest answer is that they are not in the evidence summarised here, and the approved product labelling plus a treating clinician are the appropriate sources.

Tumour Growth Endpoints in Midgut Neuroendocrine Tumours

The PROMID study was a placebo-controlled, double-blind, prospective randomised study in patients with metastatic neuroendocrine midgut tumours, in which researchers compared long-acting octreotide at 30 mg given intramuscularly each month against placebo and reported a median time to tumour progression of 14.3 months versus 6.0 months, with a hazard ratio of 0.34 (PMID 19704057). The study enrolled treatment-naive patients and used time to tumour progression as its primary endpoint, so the finding speaks to progression timing rather than to survival or to symptom relief (PMID 19704057).

A review of the antiproliferative effect of somatostatin analogues in gastroenteropancreatic neuroendocrine tumours summarised the receptor biology behind that signal and reported that stable disease, rather than objective tumour shrinkage, was the usual pattern described across the studies it surveyed (PMID 20572298). Whether tumour-control labelling applies to a given octreotide product depends on the jurisdiction and the specific formulation, a point for the prescribing specialist rather than for a general page.

Somatostatin Receptor Targeted Radiotherapy

Octreotide chemistry also underlies radiolabelled peptides used for imaging and for peptide receptor radionuclide therapy. A review of peptide receptor radiotherapy described how somatostatin receptor expression on neuroendocrine tumours is exploited by radiolabelled somatostatin analogues and traced the development of this treatment approach (PMID 30098719). Those radiopharmaceuticals are separate licensed products with their own labelling, and results reported for them are not results for octreotide therapy itself (PMID 30098719).

Areas Studied Outside the Approved Indications

Several topics that readers search for in connection with octreotide fall outside its approved labelling. The material below is included so that the published record is represented accurately, and these uses are not presented as benefits of the medicine. Decisions about any such use rest entirely with a treating clinician.

Gastrointestinal angiodysplasia and small bowel bleeding

The OCEAN study was a multicentre randomised controlled trial comparing standard of care with octreotide in angiodysplasia-related bleeding, and researchers reported a reduction in transfusion and iron requirements in the octreotide arm relative to standard care (PMID 38158089). A review of the role of octreotide in small bowel bleeding surveyed the earlier, largely observational literature in this setting (PMID 36159407), and a later review of pharmacological therapy for gastrointestinal angiodysplasia placed somatostatin analogues among the drug options discussed for recurrent bleeding (PMID 41538904).

Malignant bowel obstruction

A review titled "Octreotide for malignant bowel obstruction: twenty years after" revisited two decades of studies on symptom management in advanced cancer and reported that findings across the trials it examined were not consistent (PMID 22277783).

Postoperative pancreatic fistula and chylothorax

A 2025 review of somatostatin analogues for preventing postoperative pancreatic fistula re-examined the historical trial evidence and reported that results had been mixed, while discussing where further evaluation might be directed (PMID 40576898). A separate paper examined octreotide's role in the management of post-esophagectomy chylothorax, a setting where the available data are drawn largely from surgical case series rather than randomised trials (PMID 38391198).

Eye conditions

A review of medical treatment of cystoid macular oedema included somatostatin analogues among the pharmacological approaches it discussed (PMID 12854032), and a review of the efficacy of somatostatin analogues in diabetic retinopathy and thyroid eye disease summarised the trial record in those two conditions (PMID 19668474). Neither ophthalmic setting forms part of the approved labelling for octreotide.

Adverse Events: What Studies Report

Safety and tolerability were reported alongside efficacy in the clinical literature summarised here. The review of octreotide in acromegaly addressed tolerability as part of its appraisal of the short-acting and long-acting formulations (PMID 30754185), and the OCEAN randomised controlled trial collected adverse event data as part of its comparison of octreotide with standard of care (PMID 38158089). Because the abstracts cited here do not enumerate individual adverse reactions, none are listed on this page. The complete adverse reaction profile, including warnings, contraindications and monitoring requirements, appears in the approved prescribing information, and a physician or pharmacist can review it in the context of an individual medical history.

What the Cited Evidence Does Not Establish

• General wellness, body composition or performance outcomes. None of the papers cited on this page examined octreotide for such purposes.
• Survival endpoints. The randomised trial cited here reported time to tumour progression as its primary endpoint rather than overall survival (PMID 19704057).
• Comparative ranking against other somatostatin analogues. The reviews cited here described octreotide and the class broadly rather than ranking individual agents (PMID 20572298).
• Quantified symptom relief in carcinoid syndrome. No trial with symptom scales is included in this citation set, as noted above (PMID 20572298).

Reading the Evidence Carefully

Three distinctions help when interpreting octreotide literature. First, formulation matters: short-acting injection, depot injection and oral capsule were studied in different settings and carry different labelling. Second, endpoint matters: a hormone level, a progression interval and a transfusion count answer different questions, as the contrast between the acromegaly review (PMID 30754185) and the OCEAN trial (PMID 38158089) illustrates. Third, study design matters: randomised placebo-controlled data such as PROMID (PMID 19704057) sit on different footing from narrative reviews of case series (PMID 36159407).

For background on the molecule, its formulations and its regulatory history, see the overview page: Octreotide.

References

• Octreotide for acromegaly (Expert Review of Endocrinology & Metabolism, 2007)
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group (Journal of Clinical Oncology, 2009)
• Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors (World Journal of Gastroenterology, 2010)
• Peptide Receptor Radiotherapy Comes of Age (Endocrinology and Metabolism Clinics of North America, 2018)
• Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial (Gastroenterology, 2024)
• Role of octreotide in small bowel bleeding (World Journal of Clinical Cases, 2022)
• Pharmacological therapy for gastrointestinal angiodysplasia (Medicina Clinica, 2026)
• Octreotide for malignant bowel obstruction: twenty years after (Critical Reviews in Oncology/Hematology, 2012)
• Somatostatin Analogs for Preventing Postoperative Pancreatic Fistula: Past Evidence Reveals New Opportunities (Annals of Surgical Oncology, 2025)
• Octreotide's role in the management of post-esophagectomy chylothorax (Diseases of the Esophagus, 2024)
• Medical treatment of cystoid macular edema (Ocular Immunology and Inflammation, 2002)
• The efficacy of somatostatin analogues in the treatment of diabetic retinopathy and thyroid eye disease (Clinical Ophthalmology, 2007)